EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Oncotelic Therapeutics, Inc. (OTLC) EBIT Margin data is not available for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$250.35M |
|
-- |
|
-- |
|
$2.53M |
|
$-2.53M |
|
$364.37M |
|
$361.84M |
|
$361.84M |
|
$250.29M |
|
$250.29M |
|
$250.29M |
|
$250.29M |
|
$-2.53M |
|
$-2.47M |
|
422.23M |
|
422.23M |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$1.20M |
|
-- |
|
$391.89M |
|
$393.09M |
|
$18.14M |
|
$1.66M |
|
$113.21M |
|
$131.36M |
|
$261.73M |
|
$258.94M |
|
$261.73M |
|
442.60M |
|
| Cash Flow Statement Financials | |
$-1.38M |
|
-- |
|
$1.39M |
|
$0.11M |
|
$0.11M |
|
$0.00M |
|
$2.38M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.07 |
|
-- |
|
-- |
|
0.01 |
|
0.05 |
|
-- |
|
-- |
|
|
EBIT Margin |
-- |
-- |
|
-- |
|
-- |
|
$-1.38M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
95.63% |
|
96.66% |
|
63.67% |
|
95.03% |
|
$0.59 |
|
$-0.00 |
|
$-0.00 |
|